High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives

New England Journal of Medicine

Volumn 338, Issue 25, 1998, Pages 1793-1797

  Martinelli, Ida ^a,b   Sacchi, Elisabetta ^a   Landi, Gianluca ^a   Taioli, Emanuela ^a   Duca, Francesca ^a   Mannucci, Pier Mannuccio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VEIN THROMBOSIS;

BIOLOGY; BLOOD COAGULATION EFFECTS; CEREBROVASCULAR EFFECTS; CONTRACEPTION; CONTRACEPTIVE METHODS--SIDE EFFECTS; CORRELATION STUDIES; DEVELOPED COUNTRIES; DISEASES; EMBOLISM; EUROPE; FAMILY PLANNING; GENETICS; HEMATOLOGICAL EFFECTS; HEMIC SYSTEM; ITALY; MEDITERRANEAN COUNTRIES; ORAL CONTRACEPTIVES--SIDE EFFECTS; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; RISK FACTORS; SOUTHERN EUROPE; STATISTICAL STUDIES; STUDIES; THROMBOEMBOLISM; THROMBOSIS; VASCULAR DISEASES;

ADOLESCENT; ADULT; BLOOD COAGULATION DISORDERS; CASE-CONTROL STUDIES; CEREBRAL VEINS; CONTRACEPTIVES, ORAL; FACTOR V; FEMALE; HETEROZYGOTE; HUMANS; INTRACRANIAL EMBOLISM AND THROMBOSIS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; PREVALENCE; PROTHROMBIN; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHLEBITIS;

EID: 0032543748     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199806183382502     Document Type: Article

References (30)

1. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-44.
2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
3. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
4. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
5. Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis - a review of 38 cases. Stroke 1985;16:199-213.
6. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin 1992; 10:87-111.
7. Preter MP, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis: follow-up of 77 patients. Stroke 1996;27:243-6.
8. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996;75:393-4.
9. Dulli DA, Luzzio CC, Williams EC, Schutta HS. Cerebral venous thrombosis and activated protein C resistance. Stroke 1996;27:1731-3.
10. Deschiens MA, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27:1724-30.
11. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 1998;316:589-92.
12. Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996;27:1721-3.
13. Brey RL, Coull BM. Cerebral venous thrombosis: role of activated protein C resistance and factor V gene mutation. Stroke 1996;27:1719-20.
14. Buonanno FS, Moody DM, Ball MR, Laster DW. Computed cranial tomographic findings in cerebral sinovenous occlusion. J Comput Assist Tomogr 1978;2:281-90.
15. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996;143:1257-65.
16. Taioli E, Martinelli I, Rossi V, Crosti F, Mannucci PM. Re: "Validated questionnaire for the identification of previous personal or familial venous thromboembolism." Am J Epidemiol 1998;147:605-6.
17. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-21.
18. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50.
19. Poort SR, Bertina RM, Vos HL. Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb Haemost 1997;78:1157-8.
20. de Ronde H, Bertina RM. Laboratory diagnosis of APC resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994;72:880-6.
21. Sas G, Pepper DS, Cash JD. Plasma and serum antithrombin III: differentiation by crossed immunoelectrophoresis. Thromb Res 1975;6:87-91.
22. Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986;67:504-8.
23. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955;19:251-3.
24. SAS user's guide, version 6, 4th ed. Cary, N.C.: SAS Institute, 1990.
25. Kluft C, Lansink M. Effect of oral contraceptives on haemostatic variables. Thromb Haemost 1997;78:315-26.
26. Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM. Oral contraceptives are a risk factor for cerebral vein thrombosis. Thromb Haemost 1996;76:477-8.
27. Kierkegaard A. Incidence of acute deep vein thrombosis in two districts: a phlebographic study. Acta Chir Scand 1980;146:267-9.
28. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344: 1453-7.
29. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996;313:1127-30.
30. Einhäupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991;338:597-600. [Erratum, Lancet 1991;338:958.]